Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine

Journal of Medical Virology

Volumn 81, Issue 1, 2009, Pages 1-8

  Bergroth, Tobias ^a   Ekici, Halime ^a   Gisslén, Magnus ^b   Kinloch De Loes, Sabine ^c   Goh, Li Ean ^d   Freedman, Andrew ^e   Lampe, Fiona ^f   Johnson, Margaret A ^c   Sönnerborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

^e CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiretroviral treatment; HIV 1; M184I V; Minor populations; Resistance; Selective real time PCR

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; COMPLEMENTARY DNA; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA; VIRUS VACCINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT DURATION; TREATMENT FAILURE; VACCINATION; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; VIRUS TITRATION; WILD TYPE; AMINO ACID SUBSTITUTION; DRUG EFFECT; GENETIC SELECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; MISSENSE MUTATION; PLASMA; POLYMERASE CHAIN REACTION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLASMA; POLYMERASE CHAIN REACTION; SELECTION (GENETICS); SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 58149232923     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21363     Document Type: Article

References (25)

1. Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A. 2002. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16:1039-1044.
2. Bergroth T, Sönnerborg A, Yun Z. 2005. Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. J Virol Methods 127:100-107.
3. Boucher C, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg M, Cameron J. 1993. High-level resistance to (-) enantiomeric 2′-deoxy- 3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37:2231-2234.
4. Charpentier C, Dwyer D, Mammano F, Lecossier D, Clavel F, Hance A. 2004. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 78:4234-4247.
5. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L, Ingerman M, Witek J, Kedanis R, Natkin J, DeSimone J, Pomerantz R. 1999. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282:1627-1632.
6. Fidler S, Fraser C, Fox J, Tamm N, Griffin J, Weber J. 2006. Comparative potency of three antiretroviral therapy regimes in primary HIV infection. AIDS 20:247-252.
7. Furtado M, Callaway D, Phair J, Kunstman K, Stanton J, Macken C, Perelson A, Wolinsky S. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340:1614-1622.
8. Hammer S, Katzenstein D, Hughes M, Gundacker H, Schooley R, Haubrich R, Henry W, Lederman M, Phair J, Niu M, Hirsch M, Merigan T. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 335:1081-1090.
9. Hammer S, Squires K, Hughes M, Grimes J, Demeter L, Currier J, Eron J, Feinberg J, Balfour H, Deyton L, Chodakewitz J, Fischl M. 1997. A controlled trial of two nucleoside analogues plus indinavir in personswith human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337:725-733.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
11. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S. 2007. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 45:381-390.
12. Josephson F, Albert J, Flamholc L, Gisslen M, Karlström O, Lindgren SR, Naver L, Sandström E, Svedhem-Johansson V, Svennerholm B, Sönnerborg A. 2007. Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scand J Infect Dis 39:486-507.
13. Karlsson A, Lindkvist A, Lindbäck S, Gaines H, Sönnerborg A. 2001. Recent origin of human immunodeficiency virus type 1 variants in resting CD4+ Tlymphocytes in untreated and suboptimally treated subjects. J Infect Dis 184:1392-1401.
14. Kinloch-de Loes S, Hoen B, Smith D, Autran B, Lampe F, Phillips A, Goh L, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard P, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper D, Perrin L, Group QS. 2005. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 192:607-617.
15. Lindback S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, Blaxhult A, Sonnerborg A, Biberfeld G, Gaines H. 2000. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 14:2333-2339.
16. Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, Ruiz N, Brun S, Sun E, Perelson A, Ho D, Markowitz M. 2003. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 187:896-900.
17. Metzner K, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, Weber R, Hirschel B, Kostrikis L, Günthard H, Study TSHC. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 188:1433-1443.
18. Metzner K, Allers K, Rauch P, Harrer T. 2007. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 21:703-711.
19. Moltó J, Ruiz L, Valle M, Martinez-Picado J, Bonjoch A, Bravo I, Negredo E, Heilek-Sneider G, Clotet B. 2006. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. Antivir Ther 11:47-51.
20. Ramratnam B, Ribeiro R, He T, Chung C, Simon V, Vanderhoeven J, Hurley A, Zhang L, Perelson A, Ho D, Markowitz M. 2004. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 35:33-37.
21. Roquebert B, Malet I, Wirden M, Tubiana R, Valantin M, Simon A, Katlama C, Peytavin G, Calvez V, Marcelin A. 2006. Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS 20:287-289.
22. Schinazi R, Lloyd R, Nguyen M, Cannon D, McMillan A, Ilksoy N, Chu C, Liotta D, Bazmi H, Mellors J. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 37:875-881.
23. Svedhem V, Bergroth T, Lidman K, Sönnerborg A. 2007. Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure. HIV Med 8:504-510.
24. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J, Nicholson W. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. Aids 9:351-357.
25. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L. 2003. Drug resistance mutations during structured treatment interruptions. Antivir Ther 8:411-415.